aod9604 vs retatrutide AOD 9604 and retatrutide: evidence, risks, and UK legal status aod9604 vs retatrutide AOD 9604

This excellent safety record contributed to the peptides characterization as having tolerability indistinguishable from placebo in published research

It also supports digestive function, and can help relieve upset stomach & constipation and supports a Stronger Immune System

The cartilage finding is notable because it suggests the peptide acts through pathways relevant to connective tissue repair, not only lipolysis

The standard regimen involves: Loading doses without neurological involvement : 1 mg intramuscularly three times a week for 2 weeks [3] [8] Loading doses with neurological involvement : 1 mg intramuscularly on alternate days until no further improvement [3] [8] Maintenance therapy : 1 mg every 23 months for life in cases of pernicious anaemia or irreversible malabsorption (every 2 months if neurological involvement) [3] [8] This aggressive approach aims to prevent irreversible neurological damage, though recovery of established neuropathy may be incomplete, particularly if treatment is delayed